 | • レポートコード：D005-07373 • 出版社/出版日：GlobalInfoResearch / 2020年5月22日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール • 産業分類：医療・製薬 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、遺伝性疾患薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。遺伝性疾患薬の種類別市場規模（嚢胞性線維症（CF）、デュシェンヌ型筋ジストロフィー（DMD）、リソソーム蓄積症（LSD）、発作性夜間血色素尿症（PNH））、用途別市場規模（クリニック、病院）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：Sanofi、Sarepta、Amgen、Vertex、BioMarin、Takeda、Pfizer、GW Pharmaceuticals ・地域別グローバル市場分析 2015年-2020年 ・遺伝性疾患薬の北米市場（アメリカ、カナダ、メキシコ） ・遺伝性疾患薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・遺伝性疾患薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・遺伝性疾患薬の南米市場（ブラジル、アルゼンチン） ・遺伝性疾患薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：嚢胞性線維症（CF）、デュシェンヌ型筋ジストロフィー（DMD）、リソソーム蓄積症（LSD）、発作性夜間血色素尿症（PNH） ・用途別分析：クリニック、病院 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Genetic Disorders Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Genetic Disorders Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Genetic Disorders Drug market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Genetic Disorders Drug market has been segmented into
Cystic Fibrosis (CF)
Duchenne Muscular Dystrophy (DMD)
Lysosomal Storage Disease (LSD)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
By Application, Genetic Disorders Drug has been segmented into:
Clinic
Hospital
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Genetic Disorders Drug market presented in the report. This section sheds light on the sales growth of different regional and country-level Genetic Disorders Drug markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Genetic Disorders Drug market.
The report offers in-depth assessment of the growth and other aspects of the Genetic Disorders Drug market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Genetic Disorders Drug Market Share Analysis
Genetic Disorders Drug competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Genetic Disorders Drug sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Genetic Disorders Drug sales, revenue and market share for each player covered in this report.
The major players covered in Genetic Disorders Drug are:
Sanofi
Sarepta
Amgen
Vertex
BioMarin
Takeda
Pfizer
GW Pharmaceuticals
Among other players domestic and global, Genetic Disorders Drug market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Genetic Disorders Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Genetic Disorders Drug, with price, sales, revenue and global market share of Genetic Disorders Drug in 2018 and 2019.
Chapter 3, the Genetic Disorders Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Genetic Disorders Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Genetic Disorders Drug market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Genetic Disorders Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Genetic Disorders Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Genetic Disorders Drug Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Cystic Fibrosis (CF)
1.2.3 Duchenne Muscular Dystrophy (DMD)
1.2.4 Lysosomal Storage Disease (LSD)
1.2.5 Paroxysmal Nocturnal Hemoglobinuria (PNH)
1.3 Market Analysis by Application
1.3.1 Overview: Global Genetic Disorders Drug Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Clinic
1.3.3 Hospital
1.4 Overview of Global Genetic Disorders Drug Market
1.4.1 Global Genetic Disorders Drug Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Sanofi SWOT Analysis
2.1.4 Sanofi Product and Services
2.1.5 Sanofi Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Sarepta
2.2.1 Sarepta Details
2.2.2 Sarepta Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Sarepta SWOT Analysis
2.2.4 Sarepta Product and Services
2.2.5 Sarepta Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Amgen
2.3.1 Amgen Details
2.3.2 Amgen Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Amgen SWOT Analysis
2.3.4 Amgen Product and Services
2.3.5 Amgen Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Vertex
2.4.1 Vertex Details
2.4.2 Vertex Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Vertex SWOT Analysis
2.4.4 Vertex Product and Services
2.4.5 Vertex Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 BioMarin
2.5.1 BioMarin Details
2.5.2 BioMarin Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 BioMarin SWOT Analysis
2.5.4 BioMarin Product and Services
2.5.5 BioMarin Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Takeda
2.6.1 Takeda Details
2.6.2 Takeda Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Takeda SWOT Analysis
2.6.4 Takeda Product and Services
2.6.5 Takeda Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Pfizer SWOT Analysis
2.7.4 Pfizer Product and Services
2.7.5 Pfizer Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 GW Pharmaceuticals
2.8.1 GW Pharmaceuticals Details
2.8.2 GW Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 GW Pharmaceuticals SWOT Analysis
2.8.4 GW Pharmaceuticals Product and Services
2.8.5 GW Pharmaceuticals Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Genetic Disorders Drug Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Genetic Disorders Drug Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Genetic Disorders Drug Manufacturer Market Share in 2019
3.3.2 Top 6 Genetic Disorders Drug Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Genetic Disorders Drug Sales, Revenue and Market Share by Regions
4.1.1 Global Genetic Disorders Drug Sales and Market Share by Regions (2015-2020)
4.1.2 Global Genetic Disorders Drug Revenue and Market Share by Regions (2015-2020)
4.2 North America Genetic Disorders Drug Sales and Growth Rate (2015-2020)
4.3 Europe Genetic Disorders Drug Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Genetic Disorders Drug Sales and Growth Rate (2015-2020)
4.5 South America Genetic Disorders Drug Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Genetic Disorders Drug Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Genetic Disorders Drug Sales, Revenue and Market Share by Country
5.1.1 North America Genetic Disorders Drug Sales and Market Share by Country (2015-2020)
5.1.2 North America Genetic Disorders Drug Revenue and Market Share by Country (2015-2020)
5.2 United States Genetic Disorders Drug Sales and Growth Rate (2015-2020)
5.3 Canada Genetic Disorders Drug Sales and Growth Rate (2015-2020)
5.4 Mexico Genetic Disorders Drug Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Genetic Disorders Drug Sales, Revenue and Market Share by Country
6.1.1 Europe Genetic Disorders Drug Sales and Market Share by Country (2015-2020)
6.1.2 Europe Genetic Disorders Drug Revenue and Market Share by Country (2015-2020)
6.2 Germany Genetic Disorders Drug Sales and Growth Rate (2015-2020)
6.3 UK Genetic Disorders Drug Sales and Growth Rate (2015-2020)
6.4 France Genetic Disorders Drug Sales and Growth Rate (2015-2020)
6.5 Russia Genetic Disorders Drug Sales and Growth Rate (2015-2020)
6.6 Italy Genetic Disorders Drug Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Genetic Disorders Drug Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Genetic Disorders Drug Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Genetic Disorders Drug Revenue and Market Share by Regions (2015-2020)
7.2 China Genetic Disorders Drug Sales and Growth Rate (2015-2020)
7.3 Japan Genetic Disorders Drug Sales and Growth Rate (2015-2020)
7.4 Korea Genetic Disorders Drug Sales and Growth Rate (2015-2020)
7.5 India Genetic Disorders Drug Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Genetic Disorders Drug Sales and Growth Rate (2015-2020)
7.7 Australia Genetic Disorders Drug Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Genetic Disorders Drug Sales, Revenue and Market Share by Country
8.1.1 South America Genetic Disorders Drug Sales and Market Share by Country (2015-2020)
8.1.2 South America Genetic Disorders Drug Revenue and Market Share by Country (2015-2020)
8.2 Brazil Genetic Disorders Drug Sales and Growth Rate (2015-2020)
8.3 Argentina Genetic Disorders Drug Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Genetic Disorders Drug Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Genetic Disorders Drug Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Genetic Disorders Drug Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Genetic Disorders Drug Sales and Growth Rate (2015-2020)
9.3 Turkey Genetic Disorders Drug Sales and Growth Rate (2015-2020)
9.4 Egypt Genetic Disorders Drug Sales and Growth Rate (2015-2020)
9.5 South Africa Genetic Disorders Drug Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Genetic Disorders Drug Sales and Market Share by Type (2015-2020)
10.2 Global Genetic Disorders Drug Revenue and Market Share by Type (2015-2020)
10.3 Global Genetic Disorders Drug Price by Type (2015-2020)
11 Global Genetic Disorders Drug Market Segment by Application
11.1 Global Genetic Disorders Drug Sales Market Share by Application (2015-2020)
11.2 Global Genetic Disorders Drug Revenue Market Share by Application (2015-2020)
11.3 Global Genetic Disorders Drug Price by Application (2015-2020)
12 Market Forecast
12.1 Global Genetic Disorders Drug Sales, Revenue and Growth Rate (2021-2025)
12.2 Genetic Disorders Drug Market Forecast by Regions (2021-2025)
12.2.1 North America Genetic Disorders Drug Market Forecast (2021-2025)
12.2.2 Europe Genetic Disorders Drug Market Forecast (2021-2025)
12.2.3 Asia-Pacific Genetic Disorders Drug Market Forecast (2021-2025)
12.2.4 South America Genetic Disorders Drug Market Forecast (2021-2025)
12.2.5 Middle East & Africa Genetic Disorders Drug Market Forecast (2021-2025)
12.3 Genetic Disorders Drug Market Forecast by Type (2021-2025)
12.3.1 Global Genetic Disorders Drug Sales Forecast by Type (2021-2025)
12.3.2 Global Genetic Disorders Drug Market Share Forecast by Type (2021-2025)
12.4 Genetic Disorders Drug Market Forecast by Application (2021-2025)
12.4.1 Global Genetic Disorders Drug Sales Forecast by Application (2021-2025)
12.4.2 Global Genetic Disorders Drug Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Genetic Disorders Drug Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Genetic Disorders Drug by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Genetic Disorders Drug Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Sanofi Basic Information, Manufacturing Base and Competitors
Table 8. Sanofi Genetic Disorders Drug Major Business
Table 9. Sanofi Genetic Disorders Drug Total Revenue (USD Million) (2017-2018)
Table 10. Sanofi SWOT Analysis
Table 11. Sanofi Genetic Disorders Drug Product and Services
Table 12. Sanofi Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Sarepta Basic Information, Manufacturing Base and Competitors
Table 14. Sarepta Genetic Disorders Drug Major Business
Table 15. Sarepta Genetic Disorders Drug Total Revenue (USD Million) (2017-2018)
Table 16. Sarepta SWOT Analysis
Table 17. Sarepta Genetic Disorders Drug Product and Services
Table 18. Sarepta Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Amgen Basic Information, Manufacturing Base and Competitors
Table 20. Amgen Genetic Disorders Drug Major Business
Table 21. Amgen Genetic Disorders Drug Total Revenue (USD Million) (2017-2018)
Table 22. Amgen SWOT Analysis
Table 23. Amgen Genetic Disorders Drug Product and Services
Table 24. Amgen Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Vertex Basic Information, Manufacturing Base and Competitors
Table 26. Vertex Genetic Disorders Drug Major Business
Table 27. Vertex Genetic Disorders Drug Total Revenue (USD Million) (2017-2018)
Table 28. Vertex SWOT Analysis
Table 29. Vertex Genetic Disorders Drug Product and Services
Table 30. Vertex Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. BioMarin Basic Information, Manufacturing Base and Competitors
Table 32. BioMarin Genetic Disorders Drug Major Business
Table 33. BioMarin Genetic Disorders Drug Total Revenue (USD Million) (2017-2018)
Table 34. BioMarin SWOT Analysis
Table 35. BioMarin Genetic Disorders Drug Product and Services
Table 36. BioMarin Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Takeda Basic Information, Manufacturing Base and Competitors
Table 38. Takeda Genetic Disorders Drug Major Business
Table 39. Takeda Genetic Disorders Drug Total Revenue (USD Million) (2017-2018)
Table 40. Takeda SWOT Analysis
Table 41. Takeda Genetic Disorders Drug Product and Services
Table 42. Takeda Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Pfizer Basic Information, Manufacturing Base and Competitors
Table 44. Pfizer Genetic Disorders Drug Major Business
Table 45. Pfizer Genetic Disorders Drug Total Revenue (USD Million) (2017-2018)
Table 46. Pfizer SWOT Analysis
Table 47. Pfizer Genetic Disorders Drug Product and Services
Table 48. Pfizer Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. GW Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 50. GW Pharmaceuticals Genetic Disorders Drug Major Business
Table 51. GW Pharmaceuticals Genetic Disorders Drug Total Revenue (USD Million) (2017-2018)
Table 52. GW Pharmaceuticals SWOT Analysis
Table 53. GW Pharmaceuticals Genetic Disorders Drug Product and Services
Table 54. GW Pharmaceuticals Genetic Disorders Drug Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Global Genetic Disorders Drug Sales by Manufacturer (2018-2019) (K Doses)
Table 56. Global Genetic Disorders Drug Revenue by Manufacturer (2018-2019) (USD Million)
Table 57. Global Genetic Disorders Drug Sales by Regions (2015-2020) (K Doses)
Table 58. Global Genetic Disorders Drug Sales Market Share by Regions (2015-2020)
Table 59. Global Genetic Disorders Drug Revenue by Regions (2015-2020) (USD Million)
Table 60. North America Genetic Disorders Drug Sales by Countries (2015-2020) (K Doses)
Table 61. North America Genetic Disorders Drug Sales Market Share by Countries (2015-2020)
Table 62. North America Genetic Disorders Drug Revenue by Countries (2015-2020) (USD Million)
Table 63. North America Genetic Disorders Drug Revenue Market Share by Countries (2015-2020)
Table 64. Europe Genetic Disorders Drug Sales by Countries (2015-2020) (K Doses)
Table 65. Europe Genetic Disorders Drug Sales Market Share by Countries (2015-2020)
Table 66. Europe Genetic Disorders Drug Revenue by Countries (2015-2020) (USD Million)
Table 67. Asia-Pacific Genetic Disorders Drug Sales by Regions (2015-2020) (K Doses)
Table 68. Asia-Pacific Genetic Disorders Drug Sales Market Share by Regions (2015-2020)
Table 69. Asia-Pacific Genetic Disorders Drug Revenue by Regions (2015-2020) (USD Million)
Table 70. South America Genetic Disorders Drug Sales by Countries (2015-2020) (K Doses)
Table 71. South America Genetic Disorders Drug Sales Market Share by Countries (2015-2020)
Table 72. South America Genetic Disorders Drug Revenue by Countries (2015-2020) (USD Million)
Table 73. South America Genetic Disorders Drug Revenue Market Share by Countries (2015-2020)
Table 74. Middle East & Africa Genetic Disorders Drug Sales by Countries (2015-2020) (K Doses)
Table 75. Middle East & Africa Genetic Disorders Drug Sales Market Share by Countries (2015-2020)
Table 76. Middle East & Africa Genetic Disorders Drug Revenue by Countries (2015-2020) (USD Million)
Table 77. Middle East & Africa Genetic Disorders Drug Revenue Market Share by Countries (2015-2020)
Table 78. Global Genetic Disorders Drug Sales by Type (2015-2020) (K Doses)
Table 79. Global Genetic Disorders Drug Sales Share by Type (2015-2020)
Table 80. Global Genetic Disorders Drug Revenue by Type (2015-2020) (USD Million)
Table 81. Global Genetic Disorders Drug Revenue Share by Type (2015-2020)
Table 82. Global Genetic Disorders Drug Sales by Application (2015-2020) (K Doses)
Table 83. Global Genetic Disorders Drug Sales Share by Application (2015-2020)
Table 84. Global Genetic Disorders Drug Sales Forecast by Regions (2021-2025) (K Doses)
Table 85. Global Genetic Disorders Drug Market Share Forecast by Regions (2021-2025)
Table 86. Global Genetic Disorders Drug Sales Forecast by Type (2021-2025) (K Doses)
Table 87. Global Genetic Disorders Drug Market Share Forecast by Type (2021-2025)
Table 88. Global Genetic Disorders Drug Sales Forecast by Application (2021-2025)
Table 89. Global Genetic Disorders Drug Market Share Forecast by Application (2021-2025)
Table 90. Direct Channel Pros & Cons
Table 91. Indirect Channel Pros & Cons
Table 92. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Genetic Disorders Drug Picture
Figure 2. Global Sales Market Share of Genetic Disorders Drug by Type in 2019
Figure 3. Cystic Fibrosis (CF) Picture
Figure 4. Duchenne Muscular Dystrophy (DMD) Picture
Figure 5. Lysosomal Storage Disease (LSD) Picture
Figure 6. Paroxysmal Nocturnal Hemoglobinuria (PNH) Picture
Figure 7. Genetic Disorders Drug Sales Market Share by Application in 2018
Figure 8. Clinic Picture
Figure 9. Hospital Picture
Figure 10. Global Genetic Disorders Drug Market Status and Outlook (2015-2025) (USD Million)
Figure 11. United States Genetic Disorders Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 12. Canada Genetic Disorders Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Mexico Genetic Disorders Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Germany Genetic Disorders Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 15. France Genetic Disorders Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 16. UK Genetic Disorders Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Russia Genetic Disorders Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Italy Genetic Disorders Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 19. China Genetic Disorders Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Japan Genetic Disorders Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Korea Genetic Disorders Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 22. India Genetic Disorders Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Southeast Asia Genetic Disorders Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Australia Genetic Disorders Drug Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 25. Brazil Genetic Disorders Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Egypt Genetic Disorders Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Saudi Arabia Genetic Disorders Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 28. South Africa Genetic Disorders Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Turkey Genetic Disorders Drug Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Global Genetic Disorders Drug Sales Market Share by Manufacturer in 2019
Figure 31. Global Genetic Disorders Drug Revenue Market Share by Manufacturer in 2019
Figure 32. Top 3 Genetic Disorders Drug Manufacturer (Revenue) Market Share in 2019
Figure 33. Top 6 Genetic Disorders Drug Manufacturer (Revenue) Market Share in 2019
Figure 34. Key Manufacturer Market Share Trend
Figure 35. Global Genetic Disorders Drug Sales and Growth Rate (2015-2020) (K Doses)
Figure 36. Global Genetic Disorders Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 37. Global Genetic Disorders Drug Revenue Market Share by Regions (2015-2020)
Figure 38. Global Genetic Disorders Drug Revenue Market Share by Regions in 2018
Figure 39. North America Genetic Disorders Drug Sales and Growth Rate (2015-2020)
Figure 40. Europe Genetic Disorders Drug Sales and Growth Rate (2015-2020)
Figure 41. Asia-Pacific Genetic Disorders Drug Sales and Growth Rate (2015-2020)
Figure 42. South America Genetic Disorders Drug Sales and Growth Rate (2015-2020)
Figure 43. Middle East & Africa Genetic Disorders Drug Sales and Growth Rate (2015-2020)
Figure 44. North America Genetic Disorders Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 45. North America Genetic Disorders Drug Sales Market Share by Countries (2015-2020)
Figure 46. North America Genetic Disorders Drug Sales Market Share by Countries in 2018
Figure 47. North America Genetic Disorders Drug Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 48. North America Genetic Disorders Drug Revenue Market Share by Countries in 2018
Figure 49. United States Genetic Disorders Drug Sales and Growth Rate (2015-2020) (K Doses)
Figure 50. Canada Genetic Disorders Drug Sales and Growth Rate (2015-2020) (K Doses)
Figure 51. Mexico Genetic Disorders Drug Sales and Growth Rate (2015-2020) (K Doses)
Figure 52. Europe Genetic Disorders Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 53. Europe Genetic Disorders Drug Revenue Market Share by Countries (2015-2020)
Figure 54. Europe Genetic Disorders Drug Revenue Market Share by Countries in 2019
Figure 55. Germany Genetic Disorders Drug Sales and Growth Rate (2015-2020) (K Doses)
Figure 56. UK Genetic Disorders Drug Sales and Growth Rate (2015-2020) (K Doses)
Figure 57. France Genetic Disorders Drug Sales and Growth Rate (2015-2020) (K Doses)
Figure 58. Russia Genetic Disorders Drug Sales and Growth Rate (2015-2020) (K Doses)
Figure 59. Italy Genetic Disorders Drug Sales and Growth Rate (2015-2020) (K Doses)
Figure 60. Asia-Pacific Genetic Disorders Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 61. Asia-Pacific Genetic Disorders Drug Sales Market Share by Regions 2019
Figure 62. Asia-Pacific Genetic Disorders Drug Revenue Market Share by Regions 2019
Figure 63. China Genetic Disorders Drug Sales and Growth Rate (2015-2020) (K Doses)
Figure 64. Japan Genetic Disorders Drug Sales and Growth Rate (2015-2020) (K Doses)
Figure 65. Korea Genetic Disorders Drug Sales and Growth Rate (2015-2020) (K Doses)
Figure 66. India Genetic Disorders Drug Sales and Growth Rate (2015-2020) (K Doses)
Figure 67. Southeast Asia Genetic Disorders Drug Sales and Growth Rate (2015-2020) (K Doses)
Figure 68. South America Genetic Disorders Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 69. South America Genetic Disorders Drug Sales Market Share by Countries in 2019
Figure 70. South America Genetic Disorders Drug Revenue Market Share by Countries in 2019
Figure 71. Brazil Genetic Disorders Drug Sales and Growth Rate (2015-2020) (K Doses)
Figure 72. Argentina Genetic Disorders Drug Sales and Growth Rate (2015-2020) (K Doses)
Figure 73. Middle East and Africa Genetic Disorders Drug Revenue and Growth Rate (2015-2020) (USD Million)
Figure 74. Middle East and Africa Genetic Disorders Drug Sales Market Share by Countries in 2019
Figure 75. Middle East and Africa Genetic Disorders Drug Revenue Market Share by Countries (2015-2020)
Figure 76. Middle East and Africa Genetic Disorders Drug Revenue Market Share by Countries in 2019
Figure 77. Saudi Arabia Genetic Disorders Drug Sales and Growth Rate (2015-2020) (K Doses)
Figure 78. Egypt Genetic Disorders Drug Sales and Growth Rate (2015-2020) (K Doses)
Figure 79. Turkey Genetic Disorders Drug Sales and Growth Rate (2015-2020) (K Doses)
Figure 80. South Africa Genetic Disorders Drug Sales and Growth Rate (2015-2020) (K Doses)
Figure 81. Global Genetic Disorders Drug Sales and Growth Rate (2021-2025) (K Doses)
Figure 82. Global Genetic Disorders Drug Revenue and Growth Rate (2021-2025) (USD Million)
Figure 83. North America Sales Genetic Disorders Drug Market Forecast (2021-2025) (K Doses)
Figure 84. Europe Sales Genetic Disorders Drug Market Forecast (2021-2025) (K Doses)
Figure 85. Asia-Pacific Sales Genetic Disorders Drug Market Forecast (2021-2025) (K Doses)
Figure 86. South America Sales Genetic Disorders Drug Market Forecast (2021-2025) (K Doses)
Figure 87. Middle East & Africa Sales Genetic Disorders Drug Market Forecast (2021-2025) (K Doses)
Figure 88. Sales Channel: Direct Channel vs Indirect Channel
遺伝子分析サービスの世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Genetic Analysis Services market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Genetic Analysis Se…- 遺伝病診断の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Genetic Disease Diagnostic market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Genetic Disease Di…
- デュシェンヌ型筋ジストロフィー治療の世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Duchenne Muscular Dystrophy Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 27.7% in the forecast period of 2020 to 2025 and will expected to reach USD 2629.3 million by 2025, from USD 989.7 million in 2019.…
- 特発性肺線維症薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Idiopathic Pulmonary Fibrosis Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Idiopathic…
- 遺伝子アナライザーの世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Genetic Analyzer market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Genetic Analyzer market repo…